0.14
+1.24%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About VivoSim Labs
From its filings with the US Securities and Exchange Commission
VivoSim Labs is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VIVS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 March 2026, it reported revenue of $131,000 and a net loss of $13.8m. At that date it held total assets of $7.4m and shareholders' equity of −$1.1m.
VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies ("NAM") models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
Prior to March 2025, we were a clinical stage biotechnology company that was focused on developing FXR314 in inflammatory bowel disease ("IBD"), including ulcerative colitis ("UC"), based on demonstration of clinical promise in 3D human tissues as well as strong preclinical data. Our clinical focus was in advancing FXR314 in IBD, including UC and Crohn’s disease. We planned to start a Phase 2a clinical trial in UC in the calendar year 2025 and were also exploring the potential for combination therapies using FXR314 and approved mechanisms in preclinical animal studies and our IBD disease models.
Quoted from its 10-K, filed 14 Jul 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Aug 2013
- Employees
- 9
- Website
- organovo.com ↗
- Head office
- 11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Keith MurphyExecutive Chairman of the Board, Corporate Secretary, since 2012$789,990
- Mr. Norman StaskeyPresident, Chief Financial Officer
- Mr. Tony LialinChief Commercial Officer
- Mr. Douglas CohenLead Independent Director$132,254
- Mr. David GobelIndependent Director$132,254
- Ms. Alison MilhousIndependent Director$132,254
- Mr. Adam SternIndependent Director$124,154
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Organovo Holdings develops bioprinted human tissues for drug testing and clinical applications.
- Their 3D tissue constructs mimic human biology for accurate drug assessment.
- VivoSim Labs Inc focuses on 3D human tissues for preclinical drug development and medical solutions.
Weaknesses
- Organovo has only 6 full-time employees as of 2013.
- The company went public in 2013 with limited workforce.
- VivoSim Labs Inc employs 9 people, which is small for biotech development.
Opportunities
- Bioprinted tissues offer growth in drug discovery and predictive toxicology markets.
- 3D tissue models can expand into clinical applications like blood vessel grafts.
- The Health Care sector provides opportunities for biotechnology innovation.
Threats
- Biotechnology competition may impact Organovo's market position.
- Regulatory challenges could affect tissue development applications.
- VivoSim Labs Inc faces industry risks in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.